Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an exclusive worldwide licensing agreement for MZE001. This novel therapeutic candidate…
Sanofi, in its pursuit of a robust vaccine portfolio, has forged a co-exclusive licensing agreement with Novavax, a biotech firm headquartered in Maryland, USA. The terms of this agreement encompass several key elements: Sanofi gains a co-exclusive license to globally…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, reported today that the Phase 3 KEYNOTE-B21 trial assessing KEYTRUDA, Merck’s anti-PD-1 therapy, alongside chemotherapy as an adjuvant treatment, with or without radiotherapy, did not achieve…
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit research and development organization Medicines for Malaria Venture (MMV), has…
Soleo Health, a prominent provider of specialized pharmacy services for rare and ultra-rare diseases, has been designated as a limited distribution specialty pharmacy partner for dispensing RYPLAZIM® (plasminogen, human-tvmh), developed by Kedrion Biopharma. RYPLAZIM, the first and only FDA-approved treatment…
Lantern Pharma Inc. (NASDAQ: LTRN), a prominent player in artificial intelligence (AI)-driven oncology drug discovery and development, has announced a strategic partnership with Oregon Therapeutics, a distinguished French biotechnology company. The collaboration aims to optimize the advancement of XCE853, Oregon…
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative convertibleCAR® programs, merging the unique cell therapy platforms of both…
In January 2016, Elisa Glass began feeling fatigued and unsteady. As her symptoms worsened to include severe body aches and weakness reminiscent of painful charley horses, she sought help from her primary care physician. Initially suspected to have Lyme disease…
Amgen (NASDAQ: AMGN) has announced the unveiling of groundbreaking respiratory research at the American Thoracic Society (ATS) 2024 International Conference, scheduled from May 12 to May 22 in San Diego. The presentation will include thirteen abstracts supporting two approved medications…
AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from 17 to 22 May 2024. The company will present…
Moderna, Inc. (NASDAQ: MRNA) has unveiled plans to share insights from its extensive respiratory portfolio, encompassing vaccines and vaccine candidates targeting COVID-19 (mRNA-1273, mRNA-1283), influenza (mRNA-1010, mRNA-1011/1012), and respiratory syncytial virus (RSV) (mRNA-1345), along with data pertaining to its latent…
Takeda has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, for the…